Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,411.20
(
-2.35%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,330.00
(
-0.02%
)
News Focus
News Focus
Post# of 257299
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122816
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 231760

Thursday, 07/30/2020 4:14:35 PM

Thursday, July 30, 2020 4:14:35 PM

Post# of 257299
GILD 2Q20 HCV sales=$448M, -39% QoQ, -41% YoY. The 2Q20 geographic breakdown was: US $220M; EU $70M; RoW $158M.

During 2Q20, the COVID-19 pandemic greatly reduced HCV patient visits and hence new-patient starts, worldwide. GILD’s worldwide HCV patient starts in 2Q20 (CC slide #16) were 25K vs 45K in 1Q20 (decreasing from 29K to 17K in the US).

PR:
http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-first-quarter-2020-financial-results

CC slides:
http://investors.gilead.com/static-files/cd67608e-573e-4a6a-8131-aee5b9e2453e

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today